Conv. Plasma
Nigella Sativa

All aspirin studies
Meta analysis
study COVID-19 treatment researchAspirinAspirin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 0% Improvement Relative Risk Aspirin for COVID-19  Azizi et al.  Prophylaxis Is prophylaxis with aspirin beneficial for COVID-19? Retrospective 262 patients in Iran No significant difference in mortality Azizi et al., J. Nephropharmacology, Feb 2023 Favors aspirin Favors control

A study on the effect of aspirin on clinical symptoms, laboratory indices, and outcomes in patients with COVID-19

Azizi et al., Journal of Nephropharmacology, doi:10.34172/npj.2023.10506
Feb 2023  
  Source   PDF   All   Meta
Aspirin for COVID-19
19th treatment shown to reduce risk in March 2021
*, now known with p = 0.000061 from 71 studies, recognized in 2 countries.
Lower risk for mortality and progression.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Retrospective 131 COVID-19 patients with aspirin use and 131 matched controls in Iran, showing no significant difference in outcomes, however age matching used only two categories, 40-60 and 60+, therefore matching may be very poor given the relationship between age and COVID-19 risk. The percentages given for the control group death/recovery outcomes do not match the reported counts.
This study is excluded in the after exclusion results of meta analysis: age matching based on only two categories, matching may be very poor given the relationship between age and COVID-19 risk; inconsistent data.
risk of death, no change, RR 1.00, p = 1.00, treatment 17 of 131 (13.0%), control 17 of 131 (13.0%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Azizi et al., 17 Feb 2023, retrospective, Iran, peer-reviewed, 6 authors.
This PaperAspirinAll
A study on the effect of aspirin on clinical symptoms, laboratory indices, and outcomes in patients with COVID-19
Roham Azizi, Maryam Dehghani Mobarak, Reza Goujani, Soheil Mohsen Nabi-Afjadi, Mousavi Rizi, Ahmadreza Maghsoudi, A R T I C L E I N F O
In a cross-sectional and observational study, the case and control groups were selected based on aspirin use, with non-users divided into two groups (131 medical records of patients with COVID-19 who administered aspirin and 131 of the group of patients with COVID-19 without aspirin administration). Aspirin was found to be ineffective in treating clinical symptoms, laboratory indices, and outcomes in COVID-19 patients.
Authors' contribution The principal investigators of the present study were RA and MDM. AM contributed to the conception and design of the study and revised and revaluated the manuscript. RG conducted data analysis. MNA and SMR collected data. In addition, all authors contributed to the final manuscript, read it, approved it, and attested to its accuracy and validity. Conflicts of interest The authors declare that they have no competing interests. Ethical issues The research adhered to the principles of the Helsinki Declaration. Patients' consent was obtained with their knowledge. The permission number of 154/99/30362 was granted by the Ethics Committee in Deputy of Treatment of Social Security Organization. Moreover, the authors have identified ethical concerns (including plagiarism, data fabrication, and double publication). Funding/Support None.
Abdelhafiz, Emmerton, Sinclair, Diabetes in COVID-19 pandemic-prevalence, patient characteristics and adverse outcomes, Int J Clin Pract, doi:10.1111/ijcp.14112
Chow, Khanna, Kethireddy, Yamane, Levine et al., Aspirin Use Is Associated With Decreased Mechanical Ventilation, Intensive Care Unit Admission, and In-Hospital Mortality in Hospitalized Patients With Coronavirus Disease 2019, Anesth Analg, doi:10.1213/ANE.0000000000005292
Klok, Kruip, Van Der Meer, Arbous, Gommers et al., Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis, Thromb Res, doi:10.1016/j.thromres.2020.04.041
Mehta, Mcauley, Brown, Sanchez, Tattersall et al., HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet, doi:10.1016/S0140-6736(20)30628-0
Ornelas, Zacharias-Millward, Menter, Davis, Lichtenberger et al., Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention, Cancer Metastasis Rev, doi:10.1007/s10555-017-9675-z
Varga, Flammer, Steiger, Haberecker, Andermatt et al., Endothelial cell infection and endotheliitis in COVID-19, Lancet, doi:10.1016/S0140-6736(20)30937-5
Yang, Ng, Li, Thrombocytopenia in patients with severe acute respiratory syndrome (review), Hematology, doi:10.1080/10245330400026170
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop